Scott G. Franzblau
Director, Institute for Tuberculosis Research
Albert Schatz Professor, College of Pharmacy - Pharmaceutical Sciences
Contact
Office Phone:
Email:
Related Sites:
About Heading link
Research Interests:
1) New drug discovery for tuberculosis, non-tuberculous mycobacteria, Lyme Disease and ESKAPE pathogens
2) Antimicrobial assay development
3) Isolation of novel minor bioactive secondary metabolites
Teaching and Supervision Heading link
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PSCI Ph.D. Thesis Research (PSCI 599), 8/23/2021 – 12/3/2021
PHAR 506 (PHAR 506), 2/24/2021 – 2/24/2021
Undergrad Res Exp MedChem&Pcog (PMMP 300), 1/14/2019 – 5/3/2019
Spec Project Med Chem &Pcog (PMMP 390), 1/9/2017 – 4/28/2017
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Lab Tech in Pcog I (PMPG 590), 1/11/2016 – 4/29/2016
Selected Grants
Design, Syntheses and Studies of Novel Antituberculosis Agents, University of Notre Dame., 9/1/2021 - 8/31/2022, Obligated Amount: $92899; Anticipated Amount: $92899
Provide heat inactivated cell suspensions of four mycobacterial strains to EpicGenetics, EpicGenetics., 8/1/2021 - 1/31/2022, Obligated Amount: $3980; Anticipated Amount: $3980
In Vitro testing of candidate anti-tubercular compounds (Master under 109178), Global Alliance for TB Drug Development., 4/1/2021 - 4/30/2023, Obligated Amount: $747690; Anticipated Amount: $747690
★ Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb, Global Alliance for TB Drug Development., 4/1/2019 - 3/31/2023, Obligated Amount: $7080805; Anticipated Amount: $7080805
A new paradigm for the creation and mining of microbial libraries for drug discovery, National Institutes of Health (National Institute of General Medical Sciences)., 8/10/2018 - 7/31/2023, Obligated Amount: $2069671; Anticipated Amount: $2069671
Enhancing basic and translational TB research in northern Vietnam, National Institutes of Health., 7/1/2017 - 6/30/2022, Obligated Amount: $52396; No Anticipated Amount Set
A Novel Antibiotic Strategy Exploiting Metabolite Self-Toxicity, Chicago Biomedical Consortium., 3/1/2017 - 2/28/2019, Obligated Amount: $100000; Anticipated Amount: $100000
High-Throughput Screening and Validation of Inhibitors Against M. Tuberculosis Class II FBPase, Chicago Biomedical Consortium., 10/1/2016 - 3/31/2018, No Obligated Amount Set; No Anticipated Amount Set
★ In Vitro Testing of Candidate Anti-Tubercular Compounds (MASTER under 109178), Global Alliance for TB Drug Development., 10/1/2005 - 3/31/2021, Obligated Amount: $10312702; Anticipated Amount: $10312702
Selected Publications
Ristroph, Kurt D, McManus, Simon A, Shetye, Gauri, Cho, Sang Hyun, Lee, Dennis, Szekely, Zoltan, Sinko, Patrick J, Franzblau, Scott G, Prud’homme, Robert K. (2022). Targeted Antitubercular Peptide Nanocarriers Prepared by Flash NanoPrecipitation with Hydrophobic Ion Pairing. Advanced Materials Technologies, 2101748. doi:10.1002/admt.202101748.
Ashkar, Shireen R, Rajeswaran, Walajapet, Lee, Pil H, Yeomans, Larisa, Thrasher, Claire M, Franzblau, Scott G, Murakami, Katsuhiko S, Showalter, Hollis D, Garcia, George A. (2022). Optimization of Benzoxazinorifamycins to Minimize hPXR Activation for the Treatment of Tuberculosis and HIV Coinfection. ACS Infectious Diseases. doi:10.1021/acsinfecdis.1c00635.
Rajeswaran, Walajapet, Ashkar, Shireen R, Lee, Pil H, Yeomans, Larisa, Shin, Yeonoh, Franzblau, Scott G, Murakami, Katsuhiko S, Showalter, Hollis D, Garcia, George A. (2022). Optimization of Benzoxazinorifamycins to Improve Mycobacterium tuberculosis RNA Polymerase Inhibition and Treatment of Tuberculosis. ACS Infectious Diseases. doi:10.1021/acsinfecdis.1c00636.
Luo, Wei, Huang, Zhigang, Xu, Deming, Yang, Meng, Zhu, Yusong, Shen, Liang, Chen, Shuhui, Tao, Xin, Bin, Wang, Hu, Yinghu, Franzblau, Scott G, Jiang, Ning, Wei, Yuquan, Wei, Xiawei, Ding, Charles Z. (2022). Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorganic & Medicinal Chemistry Letters, 72, 128871. doi:10.1016/j.bmcl.2022.128871.
Huang, Zhigang, Luo, Wei, Xu, Deming, Guo, Fengxun, Yang, Meng, Zhu, Yusong, Shen, Liang, Chen, Shuhui, Tang, Dongdong, Li, Lei, Li, Yongguo, Wang, Bin, Franzblau, Scott G, Ding, Charles Z. (2022). Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorganic & Medicinal Chemistry Letters, 71, 128824. doi:10.1016/j.bmcl.2022.128824.
Pasha, Mohammad Arif, Mondal, Sumanta, Panigrahi, Naresh, Shetye, Gauri, Ma, Rui, Franzblau, Scott G, Zheng, Yong-Tang, Murugesan, Sankaranarayanan. (2022). One-Pot Synthesis of Novel Hydrazono 1,3-Thiazolidin-4-One Derivatives: Molecular Modelling, ADMET And Biological Evaluation of Anti-HIV And Anti-Tubercular Agents.. Current HIV Research, 20. doi:10.2174/1570162×20666220512163049.
Acero, Daniel, Khan, Firoz Shah Tuglak, Medina-Ortiz, Abraham J, Rivero-Cruz, Isabel, Raja, Huzefa A, Flores-Bocanegra, Laura, Fajardo-Hernández, Carlos A, Wan, Baojie, Franzblau, Scott G, Hematian, Shabnam, Figueroa, Mario. (2022). New Terpenoids from the Corticioid Fungus Punctularia atropurpurascens and their Antimycobacterial Evaluation #. Planta Medica, 88, (9-10), 729-734. doi:10.1055/a-1786-8072.
Fajardo-Hernández, Carlos A, Khan, Firoz Shah Tuglak, Flores-Bocanegra, Laura, Prieto-Davó, Alejandra, Wan, Baojie, Ma, Rui, Qader, Mallique, Villanueva-Silva, Rodrigo, Martínez-Cárdenas, Anahí, López-Lobato, Marian A, Hematian, Shabnam, Franzblau, Scott G, Raja, Huzefa A, García-Contreras, Rodolfo, Figueroa, Mario. (2022). Insights into the Chemical Diversity of Selected Fungi from the Tza Itzá Cenote of the Yucatan Peninsula. ACS Omega, 7, (14), 12171-12185. doi:10.1021/acsomega.2c00544.
Choi, Peter J, Lu, Guo-Liang, Sutherland, Hamish S, Giddens, Anna C, Franzblau, Scott G, Cooper, Christopher B, Denny, William A, Palmer, Brian D. (2022). Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-α]pyrimidin-7-amine. Tetrahedron Letters, 90, 153611. doi:10.1016/j.tetlet.2021.153611.
Education
Degrees:
B.S, Rutgers University, United States, 1976
MS, University of Arizona, United States, 1978
PhD, University of Arizona, United States, 1982
Postgraduate Training:
Postgraduate, Kurume University, Japan, 1984